Ascentage Pharma, a China-based drug maker, has raised $126.4m from a US IPO that will primarily support its two late-stage cancer therapies. Currently, its only commercial product is olverembatinib, approved as a treatment for some chronic myeloid leukaemia patients in China. The IPO funds will also support the development and potential commercial launch of its blood cancer drug, lisaftoclax. Ascentage has been trading on the Hong Kong Stock Exchange since 2019.
Regional healthcare systems report data breaches affecting more than 1.5 million
Two US healthcare networks, Connecticut’s Community Health Center Inc. and California’s NorthBay Healthcare Corporation, have reported data breaches affecting over 1.5 million people. Patient data
